Dear Stakeholders,
I want to take a moment to update you on our progress with the development of Ocumetics’ accommodative intraocular lens (AIOL), which will soon undergo its first-in-human (FIH) trials.
As you know, we are committed to pioneering advanced ophthalmic technologies that will transform the way we treat cataracts and other vision conditions. In recent internal testing of our AIOL, we identified an opportunity to make key design improvements that will enhance both its performance and safety profile. These important improvements do not require significant costs or delays, but they do require adjustments to our current manufacturing process.
To implement these changes, we will need to reorder raw materials, create new lens moulds, and conduct additional internal testing to ensure the lens meets the highest safety, efficacy, and regulatory standards. As a result, we are adjusting our timeline for the first-in-human surgeries. We now anticipate that the FIH trials will begin approximately 6-8 weeks from our previously published date.
I want to emphasize that this decision, though it results in a delay, reflects our unwavering commitment to delivering a product that meets the highest possible standards. Moving a product from concept to human trials is a rigorous process, and it is essential that we maintain the highest level of quality and safety at every stage. These enhancements to the AIOL will improve its overall performance and ensure that we are providing the best possible solution for those impacted by cataracts and other vision challenges.
I am confident that this improvement will result in a more effective, safe, and reliable lens that will set new benchmarks in the ophthalmic industry.
Thank you for your continued support as we strive to bring this transformative technology to market.
Best Regards,
Dean Burns
President & CEO
Ocumetics Technology Corp.
Key Highlights Vision performance: Clinical outcomes exceed expectations, with all patients experiencing continuing vision improvements Safety profile: Continues to meet expectations Quality-of-life improvements: Anecdotally, all patients reported life changing results from lens implantations Technology validation: Results reinforce the expected performance of Ocumetics’ inaugural accommodating intraocular lens Momentum: Forward momentum continues, with lens design enhancements
Key Highlights No material change: There is no material change in the business affairs of Ocumetics. Attendance at ASCRS: Productive ASCRS meetings with major global ophthalmic leaders. Clinical and development momentum: Feedback supported positive results from the First-in-Human (FIH) Group 1 study while the Company advances toward Group 2 patient recruitment and upcoming surgeries. Regulatory
Key Highlights Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world. Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts. Calgary, Canada – TheNewswire – April 1, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSV:V OTC) (OTCQB: OTCFF) (FRA:
Key Highlights Breakthrough Accommodating Interocular Lens Design: The enhanced lens design introduces several novel concepts that are expected to improve substantially upon the consistency, durability, and manufacturability of the lens. Enhanced Performance with Greater Reliability: This next-generation technology is anticipated to deliver natural optical responsiveness and improved mechanical stability, supporting excellent vision across its full
